{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:55:06Z","timestamp":1790999706877,"version":"4.1.0"},"reference-count":44,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7759-26","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:56Z","timestamp":1790633516000},"source":"Crossref","is-referenced-by-count":0,"title":["Coexistence of Clonally Unrelated Acute Myeloid Leukemia Harboring &lt;i&gt;CBFB::MYH11&lt;\/i&gt; and Lymphoplasmacytic Lymphoma Harboring &lt;i&gt;MYD88&lt;\/i&gt; L252P Mutation"],"prefix":"10.2169","author":[{"given":"Kodama","family":"Shimanaka","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Tsukuba Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Makishima","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Tsukuba Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Tsukuba Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"Suma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Tsukuba Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Suehara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Nishikii","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Medicine, University of Tsukuba, Japan"},{"name":"Division of Advanced Hemato-Oncology, Transborder Medical Research Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kotchetkov R, Ellison E, McLean J, et al. Synchronous dual hematological malignancies: new or underreported entity? Hematology 23: 1-4, 2018.","DOI":"10.1080\/10245332.2018.1466428"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chalopin T, Vallet N, Arbion F, et al. Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo2study). Ann Hematol 98: 2367-2377, 2019.","DOI":"10.1007\/s00277-019-03778-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 96: 454-458, 2011.","DOI":"10.3324\/haematol.2010.033779"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bucelli C, Fattizzo B, Cattaneo D, et al. Co-occurrence of myeloid and lymphoid neoplasms: clinical characterization and impact on outcome. A single-center cohort study. Front Oncol 11: 701604, 2021.","DOI":"10.3389\/fonc.2021.701604"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Castillo JJ, Olszewski AJ, Hunter ZR, et al. Incidence of secondary malignancies among patients with Waldenstr\u00f6m macroglobulinemia: an analysis of the SEER database: Waldenstr\u00f6m macroglobulinemia. Cancer 121: 2230-2236, 2015.","DOI":"10.1002\/cncr.29334"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancers in Waldenstr\u00f6m macroglobulinemia. Ann Oncol 23: 411-415, 2012.","DOI":"10.1093\/annonc\/mdr119"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gavriatopoulou M, Ntanasis-Stathopoulos I, Spiliopoulou V, et al. Second primary malignancies and disease transformation in patients with symptomatic Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma Leuk 25: e818-e825.e2, 2025.","DOI":"10.1016\/j.clml.2025.06.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenstr\u00f6m macroglobulinemia according to patterns of familial aggregation. Blood 115: 4464-4471, 2010.","DOI":"10.1182\/blood-2009-10-247973"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kristinsson SY, Bj\u00f6rkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia patients: a population-based study in Sweden. Blood 112: 3052-3056, 2008.","DOI":"10.1182\/blood-2008-06-162768"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hanzis C, Ojha RP, Hunter Z, et al. Associated malignancies in patients with Waldenstr\u00f6m\u2019s macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk 11: 88-92, 2011.","DOI":"10.3816\/CLML.2011.n.016"},{"key":"11","unstructured":"11. WHO Classification of Tumors Editorial Board, ed. Haematolymphoid tumors. WHO Classification of Tumours, 5th edition, 2024."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shimizu T, Satoh T, Tamura K, et al. Oxaliplatin\/fluorouracil\/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol 12: 218-223, 2007.","DOI":"10.1007\/s10147-007-0658-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia. Blood 128: 1321-1328, 2016.","DOI":"10.1182\/blood-2016-04-711234"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760, 2009.","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics 43: 11.10.1-11.10.33, 2013.","DOI":"10.1002\/0471250953.bi1110s43"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31: 213-219, 2013.","DOI":"10.1038\/nbt.2514"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ball S, Neupane S, Newman H, et al. Synchronous dual hematologic neoplasms of myeloid and lymphoid lineage are of common clonal origin. Blood 144: 4578-4578, 2024.","DOI":"10.1182\/blood-2024-210599"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tiacci E, Venanzi A, Ascani S, et al. High-risk clonal hematopoiesis as the origin of AITL and NPM1-mutated AML. N Engl J Med 379: 981-984, 2018.","DOI":"10.1056\/NEJMc1806413"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Holst JM, Pedersen MB, Enemark MB, et al. Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma. Haematologica 109: 4067-4072, 2024.","DOI":"10.3324\/haematol.2023.283798"},{"key":"20","unstructured":"20. Wobst J, Ruge H, Senk S, et al. Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin. Leukemia. Forthcoming."},{"key":"21","unstructured":"21. Tian T, Chen X, Xie J, et al. Clonal analysis of a patient with polycythemia Vera and coexisting chronic Lymphocytic leukaemia. Ann Clin Lab Sci 49: 671-674, 2019."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zhang J, Ma J, Li Y, et al. Whole-genome sequencing reveals cellular origin of concomitant chronic lymphocytic leukemia and multiple myeloma: a case report. Cancer Biol Ther 25: 2403203, 2024.","DOI":"10.1080\/15384047.2024.2403203"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rodriguez S, Celay J, Goicoechea I, et al. Preneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma. Sci Adv 8: eabl4644, 2022.","DOI":"10.1126\/sciadv.abl4644"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Stacey SN, Zink F, Halldorsson GH, et al. Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet 55: 2149-2159, 2023.","DOI":"10.1038\/s41588-023-01555-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yeung J, Philbrook SY, Uible E, et al. MYD88 mutations in clonal hematopoiesis promote inflammation and hematopoietic stem cell expansion. bioRxivorg. 2025.","DOI":"10.1101\/2025.06.19.660202"},{"key":"26","unstructured":"26. Lee K, Hong C-L, Dissanayake W, et al. Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis. Blood. Forthcoming."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Herbrich S, Chaib M, Anandhan S, et al. TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. Cancer Cell 44: 187-202.e7, 2026.","DOI":"10.1016\/j.ccell.2025.09.011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nguyen YTM, Fujisawa M, Ishikawa S, Sakata-Yanagimoto M. Clonal hematopoiesis and solid cancers. Cancer Sci 116: 2055-2063, 2025.","DOI":"10.1111\/cas.70097"},{"key":"29","unstructured":"29. Pich O, Bernard E, Zagorulya M, et al. Tumor-infiltrating clonal hematopoiesis. N Engl J Med 392: 1594-1608, 2025."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zambetti NA, Ping Z, Chen S, et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 19: 613-627, 2016.","DOI":"10.1016\/j.stem.2016.08.021"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Dong L, Yu W-M, Zheng H, et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 539: 304-308, 2016.","DOI":"10.1038\/nature20131"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chen L, Bian Y, Pronk E, et al. An inflammatory T-cell-stromal axis contributes to hematopoietic stem\/progenitor cell failure and clonal evolution in human myelodysplastic syndrome. Nat Commun 16: 10041, 2025.","DOI":"10.1038\/s41467-025-65802-z"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer 4: 27-42, 2023.","DOI":"10.1038\/s43018-023-00518-x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471: 235-239, 2011.","DOI":"10.1038\/nature09727"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhang J, Vlasevska S, Wells VA, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov 7: 322-337, 2017.","DOI":"10.1158\/2159-8290.CD-16-1417"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov 7: 38-53, 2017.","DOI":"10.1158\/2159-8290.CD-16-0975"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Bagratuni T, Theologi O, Vlachos C, et al. Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenstr\u00f6m macroglobulinemia. Blood 146: 3086-3097, 2025.","DOI":"10.1182\/blood.2025030177"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Li J, Chin CR, Ying H-Y, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun 15: 2879, 2024.","DOI":"10.1038\/s41467-024-47012-1"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123: 1637-1646, 2014.","DOI":"10.1182\/blood-2013-09-525808"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121: 4504-4511, 2013.","DOI":"10.1182\/blood-2012-06-436329"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374: 2209-2221, 2016.","DOI":"10.1056\/NEJMoa1516192"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059-2074, 2013.","DOI":"10.1056\/NEJMoa1301689"},{"key":"43","unstructured":"43. Patel JP, G\u00f6nen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366: 1079-1089, 2012."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Inoue D, Polaski JT, Taylor J, et al. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nat Genet 53: 707-718, 2021.","DOI":"10.1038\/s41588-021-00828-9"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7759-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:20Z","timestamp":1790998220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7759-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7759-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7759-26"}}